Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) was awarded both the Best New Drug...
Eisai Co. Ltd. announced today that TIME has selected Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in...